Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO

August 14, 2014 By Brad Perriello

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles Pershing IPO

Hedge fund mogul William Ackman and his Pershing Square Capital Management are facing an insider trading probe by the U.S. Securities & Exchange Commission over the hostile takeover bid for Allergan (NYSE:AGN) by Pershing Square and Valeant Pharmaceuticals, according to news reports.

Ackman and Valeant have been pressing for months for a proxy vote to oust Allergan’s board and replace it with a roster of their own candidates who would approve the $43.7 billion merger. Allergan has alleged in a lawsuit that its unwanted suitors broke insider trading laws in pursuing the union.

The battle isn’t keeping either Allergan or Ackman from getting on with business. Allergan today announced a deal for Taris Biomedical’s Phase II bladder drug, Liris, that’s worth up to $588 million. And Bloomberg reported that Ackman, undaunted by the SEC investigation, dangled the possibility of an IPO for Pershing Square.

The Wall Street Journal, citing "people familiar with the matter," said today that the SEC’s civil probe "is focused on potential breaches of insider trading laws."

"The inquiry is at a relatively early stage and may not lead to any enforcement action," according to the newspaper. "Regulators often look closely at novel or unusual developments in the market, and many investigations go nowhere."

"We are confident that the trading was completely lawful," Valeant told the Journal in a prepared statement today.

The SEC investigation isn’t the only government scrutiny facing the hostile takeover. Earlier this week, the Federal Trade Commission made a 2nd request for information about Valeant’s offer.

Nortech Systems closing one plant, selling two others
Nortech Systems (NSDQ:NSYS) announced this week that it will shutter one manufacturing plant and sell two others to lease them back following a tough year for the business. Maple Grove, Minn.-based Nortech said Tuesday that it will close its plant in Merrifield, Minn., by December 31, 2020, and offer that plant’s 60 employees jobs at its… […]
CMS proposes coverage updates that could increase access to VADs
The Centers for Medicare & Medicaid Services (CMS) today proposed coverage policy updates meant to increase access to VADs and artificial hearts. The policy updates, if approved, could be good news for major VAD makers Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) — as well as people with heart failure who are waiting for a heart transplant or don’t… […]
Exceeding regulatory requirements: Beyond the checklist
Many manufacturers run into issues as they adjust their devices and testing plans to meet updated regulatory requirements. Using a risk-based approach to predict and mitigate risks can help prevent costly setbacks. Sherry Parker, WuXi AppTec Between the EU Medical Device Regulation (MDR) delay and other regulatory bodies shifting priorities due to COVID-19, manufacturers are… […]
FDA medical device user fees to increase 7% in 2021
By Stewart Eisenhart, Emergo Group The US Food and Drug Administration plans a 7% medical device user fee increases for the 2021 fiscal year, raising costs slightly for premarket submissions including 510(k) Premarket Notifications, Premarket Authorizations (PMA) and De Novo requests for classification. Get the full story here at the Emergo Group’s blog. The opinions… […]
MedAcuity advising Ventilator Project on software
MedAcuity Software (Westford, Mass.) announced today that it has volunteered to provide technical software assessment for The Ventilator Project, a non-profit working on developing a low-cost ventilator specifically for COVID-19 patients. Founded in March 2020 by entrepreneur Tyler Mantel of Watertower Robotics, The Ventilator Project has built a team of more than 250 volunteers from… […]
Hologic applies for pooled COVID-19 testing nod
Hologic (NSDQ:HOLX) announced today that it has self-validated use of its Aptima and Panther Fusion molecular diagnostic COVID-19 assays with pooled patient samples and applied for an FDA emergency use authorization (EUA) for pooled testing. Marlborough, Mass.-based Hologic is the third major company to announce it is seeking such authorization. Quest Diagnostics (NYSE:DGX) gained a pooled-sample testing EUA in July,… […]
Canon Medical launches mobile digital X-ray platform
Canon Medical Systems USA announced that it has launched a mobile digital X-ray system designed to streamline bedside exams to help improve workflow and productivity. The FDA 510(k)-cleared Soltus 500 has a compact design with features that promote efficiency and patient safety, without compromising image quality. They include: Intuitive tubehead controls, including an 8.4-in. touchscreen… […]
Electronic Valve Technology
The following is an overview of different technologies available when selecting the correct electronic valve for your application. Spider Valve Technology Invented and patented by Clippard, this deceptively simple design features only one moving part with a mere 0.007″ of travel. The spider is an armature spring that undergoes a variety of proprietary processes, including… […]
FDA opens umbrella authorization for surgical masks
Faced with a growing number of coronavirus cases and a shortage of personal protective equipment (PPE), the FDA has extended emergency use authorizations (EUAs) to certain surgical masks that are not protective against small airborne particles. Unlike N95 and some KN95 respirators, these masks “may be effective in blocking splashes and large particle droplets,” the… […]
Medtech and COVID-19: 7 things you need to know
When COVID-19 set upon the U.S. in March, medtech executives only had a month at most to explain to analysts in quarterly calls how the pandemic was hitting their companies — not nearly enough time to understand the long-term impact. Three more months have passed since those quarterly calls, and we’re now wrapping up a… […]
Report: Will Dr. Hahn crack under political pressure?
Many jobs have come with increased stress levels during the coronavirus pandemic, from ICU staff to Walmart greeters. Now officials who’ve been keeping tabs on FDA commissioner Dr. Stephen Hahn are wondering whether he can weather the strain of defending science while working for the Trump administration, according to a New York Times report. Hahn… […]